Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 75-84

  Carbonell Esteve, Josep L ^a   Riverón, Ana M ^b   Cano, Mariela ^b   Ortiz, Alma I ^c   Valle, Aleta ^b   Texidó, Carlos S ^b   Tomasi, Giuseppe ^d  

^a Mediterranea Medica Clinic   (Spain)

^b Eusebio Hernández Obstetrics Teaching Hospital   (Cuba)

^c Alemán Hospital   (Nicaragua)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antiprogestins; Fibroid; Leiomyoma; Mifepristone

Indexed keywords

HEMOGLOBIN; MIFEPRISTONE;

AMENORRHEA; ARTICLE; CLINICAL IMPROVEMENT; CONTROLLED STUDY; CUBA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FATIGUE; FEMALE; HOT FLUSH; HUMAN; INFANT; LEIOMYOMA; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; NAUSEA; NICARAGUA; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; TREATMENT DURATION; UTERUS; UTERUS MYOMA; VAGINA BLEEDING; VOMITING;

EID: 84859080546     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s28103     Document Type: Article

References (30)

1. Day BD, Dunson DB, Hill MC, Coousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107.
2. Wegienka G, Baird DD, Hertz-Piccioto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol.2003;101(3):431-437.
3. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol.1994;83(4):549-555.
4. Wilson EA, Yang F, Reese E. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol.1980;55(1):20-24.
5. Andersen J. Factors in fibroid growth. Baillieres Clin Obstet Gynaecol.1998;12(2):225-243.
6. Reim MS, Barbier RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myoma. Am J Obstet Gynecol. 1995; 172(1 Pt 1):14-18.
7. Steinauer J, Pritts EA, Jackson R, Jacoby A. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol.2004;103(6):1331-1336.
8. Engman M, Granber S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod.2009;24(8):1870-1879.
9. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol.2003;101(2):243-250.
10. Alvarez-Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metabol. 1993;76(2):513-517.
11. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol. 1994;170(6): 1623-1628.
12. Yang Y, Zheng S, Li K. Treatment of uterine leiomyomata by two different doses of mifepristone. Zhonghua Fu Chan Ke Za Zhi.1996;31(10):624-626. Chinese.
13. Zeng C, Gu M, Huang H. A clinical control study on the treatment of uterine leiomyomata with gonadotropin releasing hormone agonist or mifepristone. Zhonghua Fu Chan Ke Za Zhi. 1998;33(8):490-492. Chinese.
14. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick D. Twelve- month safety and efficacy of low-dose mifepristone for uterine myomas. J Min Invasiv Gynecol. 2005;12(3):227-233.
15. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomized double-blind placebo- controlled trial. Aust NZJ Obstet Gynecol. 2009;49(1):77-83.
16. Carbonell JL, Acosta R, Heredia B, Pérez Y, Yero MC, Valle A. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008;112(5):1029-1036.
17. Carbonell JL, Quiróz Rámirez GM, Borge A, Castellón Zapata LE, Cuadra Aragón W, Giuseppe Tomasi G. Mifepristone 5 mg versus 10 mg daily for treatment of leiomyoma. Prog Obstet Gynecol.2009;10:1-8.
18. Carbonell JL, Acosta R, Heredia B, et al. Evolution of uterine leiomyoma after treatment with mifepristone: a randomized clinical trial. Prog Obstet Ginecol. 2010;53(6):231-236.
19. Carbonell JL, Acosta R, Heredia B, et al. Mifepristone for treatment of uterine fibroids. Rev Cub Gynecol Salud Reprod. 2010;36(2):236-250.
20. Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1381-1387.
21. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Openlabel study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol. 2009;146(2):215-218.
22. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18(1):61-68.
23. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. US Department of Health and Human Services, July 2009. Available from: http://www.ccd.org.cn/ccd/fs/web_edit_file/20090807144518.pdf. Accessed February 13, 2012.
24. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol.2008;21(5):591-598.
25. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update.2007;13(6):567-580.
26. Faul F. G*Power version 3.0.10. Kiel, Germany: Universitat Kiel; 2008.
27. Fiscella F, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42(7):947-953.
28. Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4121, a selective progesterone receptor modulator. Mod Pathol. 2009;22(3):450-459.
29. Levens ED, Potlog-Nahari C, Armstrong A, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol.2008;111(5):1129-1136.
30. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril.2011;95(2):767-772.